1-allyl-6-(2-chloropyrimidin-4-yl)-1H-indole | 1027635-70-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-allyl-6-(2-chloropyrimidin-4-yl)-1H-indole
• 英文别名: 6-(2-chloropyrimidin-4-yl)-1-prop-2-enylindole
• CAS: 1027635-70-6
• 化学式: C₁₅H₁₂ClN₃
• 分子量: 269.733
• InChiKey: DJGOKBXZRAMPGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-((烯丙氧基)甲基)-4-(2-(吡咯烷-1-基)乙氧基)苯胺 、 1-allyl-6-(2-chloropyrimidin-4-yl)-1H-indole 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 盐酸 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 21.0h， 生成 (16Z)-11-(2-pyrrolidin-1-ylethoxy)-14-oxa-5,7,19,28-tetrazapentacyclo[17.5.2.12,6.18,12.022,26]octacosa-1(25),2(28),3,5,8(27),9,11,16,20,22(26),23-undecaene
  参考文献：
  名称：

  WO2008/60248

  摘要：

  公开号：
• 作为产物：
  描述：

  吲哚-6-硼酸 在 四(三苯基膦)钯 、 水 、 sodium hydride 、 碳酸氢钠 作用下， 以 乙二醇二甲醚 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 6.5h， 生成 1-allyl-6-(2-chloropyrimidin-4-yl)-1H-indole
  参考文献：
  名称：

  Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis

  摘要：

  Herein, we describe the synthesis and SAR of a series of small molecule macrocycles that selectively inhibit JAK2 kinase within the JAK family and FLT3 kinase. Following a multiparameter optimization of a key aryl ring of the previously described SB1518 (pacritinib), the highly soluble 141 was selected as the optimal compound. Oral efficacy in the murine collagen-induced arthritis (CIA) model for rheumatoid arthritis (RA) supported 141 as a potential treatment for autoimmune diseases and inflammatory disorders such as psoriasis and RA. Compound 141 (SB1578) was progressed into development and is currently undergoing phase 1 clinical trials in healthy volunteers.

  DOI：

  10.1021/jm201454n

文献信息

• [EN] INDOLE SUSTITUTED PYRIMIDINES AND USE THEREOF IN THE TREATMENT OF CANCER<br/>[FR] PYRIMIDINES SUBSTITUÉES PAR INDOLE, ET LEUR UTILISATION DANS LE TRAITEMENT D'UN CANCER
  申请人：S BIO PTE LTD

  公开号：WO2008060248A1

  公开（公告）日：2008-05-22

  [EN] The present invention relates to pyrimidine compounds of formula (I) that are useful as anti proliferative agents. More particularly, the present invention relates to indole substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers.
  [FR] La présente invention concerne des composés de pyrimidine de formule (I) utiles en tant qu'agents antiprolifératifs. Plus particulièrement, la présente invention concerne des composés de pyrimidine substitués par indole, leur procédé de préparation, des compositions pharmaceutiques contenant ces composés et l'utilisation de ces composés dans le traitement de troubles prolifératifs. Ces composés peuvent être utiles en tant que médicaments pour le traitement de plusieurs troubles prolifératifs, y compris des tumeurs et des cancers.
• Discovery of the Macrocycle (9<i>E</i>)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis
  作者：Anthony D. William、Angeline C.-H. Lee、Anders Poulsen、Kee Chuan Goh、Babita Madan、Stefan Hart、Evelyn Tan、Haishan Wang、Harish Nagaraj、Dizhong Chen、Chai Ping Lee、Eric T. Sun、Ramesh Jayaraman、Mohammad Khalid Pasha、Kantharaj Ethirajulu、Jeanette M. Wood、Brian W. Dymock

  DOI：10.1021/jm201454n

  日期：2012.3.22

  Herein, we describe the synthesis and SAR of a series of small molecule macrocycles that selectively inhibit JAK2 kinase within the JAK family and FLT3 kinase. Following a multiparameter optimization of a key aryl ring of the previously described SB1518 (pacritinib), the highly soluble 141 was selected as the optimal compound. Oral efficacy in the murine collagen-induced arthritis (CIA) model for rheumatoid arthritis (RA) supported 141 as a potential treatment for autoimmune diseases and inflammatory disorders such as psoriasis and RA. Compound 141 (SB1578) was progressed into development and is currently undergoing phase 1 clinical trials in healthy volunteers.
• WO2008/60248
  申请人：——

  公开号：——

  公开（公告）日：——